Introduction
The placenta is a multifunctional organ characterized by a large proportion of invasive cells that participate in the implantation of the blastocyst into the uterine wall and by extensive neovascularization. The latter is important for the transport of soluble substances between the fetus and the mother. In fact, the term "angiogenesis" was coined to describe the formation of new blood vessels in the placenta (Folkman and Klagsbrun, 1987) . Another characteristic feature of the placenta is its regulatory function. It is well known that the placenta produces chorionic gonadotropin, placental progesterone, t 1990 by The American Society for Cell Biology and placental lactogen. In recent studies, the placenta also has been found to contain a number of growth factors (reviewed in Ohlsson, 1989) , including insulin-like growth factor-I (Wang et aL., 1988) ; insulin-like growth factor-11 (Ohisson etal., 1989) ; platelet-derived growth factor (Goustin et aL., 1985) ; interleukin-1 (Flynn et aL., 1982) ; interleukin-2 (Boehm et aL., 1989) ; transforming growth factor-: (Frolik et aL., 1983) ; and fibroblast growth factor (FGF), which is known to be a potent stimulator of angiogenesis (Moscatelli et aL., 1986) .
Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45-kDa protein that stimulates growth and chemotaxis of endothelial cells in vitro and angiogenesis in vivo . In contrast to angiogenic factors of the FGF family (Rifkin and Moscatelli, 1989) , PD-ECGF does not stimulate the growth of fibroblasts and has no affinity for heparin. PD-ECGF has been purified from human platelet lysate (Miyazono et aL., 1987) , and its cDNA was recently cloned from a human placenta cDNA library ; the predicted sequence has no striking similarity with other known proteins. Analysis of the production of PD-ECGF by cultured cells revealed that it is synthesized by human foreskin fibroblasts and by certain cancer cell lines. Consistent with the finding that the primary product lacks a signal sequence, PD-ECGF was found to be inefficiently secreted from the producer cells (Usuki etal., 1989) .
It is an interesting possibility that the angiogenesis that occurs during the development of the placenta is stimulated by soluble factors. We describe in this article that human term placenta contains large amounts of PD-ECGF. Nterminal amino acid sequencing of PD-ECGF purified to homogeneity from term placenta revealed that it is differently processed compared with the platelet form. Immunohistochemical stainings revealed that PD-ECGF is present in stromal cells of the placenta. The possibility that PD-ECGF has a function in the normal development of the placenta is discussed. PD-ECGF purified from human platelet lysate was run in parallel as a control; it occurs as a doublet of -45 kDa, probably because of proteolysis during preparation .
Results
Presence of PD-ECGF in human term placenta
Immunoblotting using a specific rabbit antiserum against PD-ECGF was used to explore the possibility that 578 PD-ECGF is present in human placenta. A placental extract was first subjected to a crude fractionation using ammonium sulfate precipitation; material precipitating between 28% and 42% saturation of ammonium sulfate, where PD-ECGF should be found ), was analyzed. An immunoblotted component of 45 kDa was seen, which was of approximately the same size as PD-ECGF purified from human platelets run in parallel ( Figure  1 ). Based on the stainability of the immunoblotted material in comparison with known amounts of PD-ECGF purified from platelets, it was estimated that placental extract contained several milligrams of PD-ECGF per placenta (data not shown).
Purification of PD-ECGF To allow a structural and functional characterization of placental PD-ECGF we purified it using an extract from a term human placenta as starting material. The purification was performed essentially as described for the purification of PD-ECGF from human platelet lysate, using QAE-Sephadex chromatography and ammonium sulfate precipitation, followed by chromatographies by anion exchange, high-performance hydroxylapatite, and alkyl-Superose . However, a QSepharose column was used rather than DEAESepharose in the anion exchange step because it was found to give a higher resolution and recovery. In addition, two steps had to be added to obtain a homogeneous product: gel chromatography on a Superose 12 column and anion exchange chromatography on an FPLC Mono Q column. In the last step, two protein peaks, both containing growth-promoting activity, eluted at '-150 mM NaCI (Figure 2A ). The protein composition of individual fractions of the Mono Q chromatogram was analyzed by sodium dodecyl sulfate (SDS)-gel electrophoresis and silver staining ( Figure 2B ). The Figure 4A ). Maximal stimulation of the purified sample occurred at -35 ng/ml, i.e. at a similar concentration as for platelet PD-ECGF (30 ng/ml) . As previously observed for PD-ECGF purified from human platelets, the activity decreased at higher concentrations of placental PD-ECGF. The endothelial growth-promoting activity given by 35 ng/ml of Vol. 1, July 1990 pure material was completely inhibited by an antiserum raised against platelet PD-ECGF but not by nonimmune serum ( Figure 4B ).
PD-ECGF also stimulated DNA synthesis in two choriocarcinoma cell lines, JAR and JEG-3 ( Figure 5 ). Maximal activity was observed at -30 ng/ml of PD-ECGF. The decrease in activity on porcine aortic endothelial cells seen at high concentration was also observed in both of the two choriocarcinoma cell lines.
Immunohistochemical localization of PD-ECGF in sections of human placenta A rabbit antiserum made against PD-ECGF purified from platelets was used to localize PD-ECGF in sections of human term placenta by an immunoperoxidase staining technique. As seen in Figure 6D , strong positive staining was seen in the stromal parts of the villi, mainly in the multipotent stromal cells and also diffuse in (Bradford, 1976 Figure 6 , B and A, represents higher magnifications of sections stained with PD-ECGF immune serum and preimmune serum, respectively. In addition to the diffuse stromal staining, there is staining along the sinusoid and at the top of the trophoblasts ( Figure 6B ).
To investigate which cell types produce PD-ECGF, we also stained parallel sections with antibodies against Factor VIII to visualize endothelial cells ( Figure 6E ) and with antibodies against human chorionic gonadotropin (HCG) to demonstrate trophoblasts ( Figure 6H ). Figure  6G is van Gieson staining of corresponding areas, showing that some villi contain an abundance of collagen.
Discussion
We show in the present study that PD-ECGF, an angiogenic factor originally purified from hu- The N-terminal sequence of PD-ECGF deduced from the cDNA ) is shown; the amino acid sequence obtained by sequencing of placental PD-ECGF is indicated by arrows and the N-terminal sequence of platelet PD-ECGF underlined. The vertical arrows denote cleavage sites for PD-ECGF purified from placenta and platelets. 580 man platelets, is present at high quantities in human term placenta. Based on quantitative immunoblotting and the total amount of mitogenic activity for PAE cells, it was estimated that one placenta contained several milligrams of PD-ECGF, which is considerably more than can be accounted for by the PD-ECGF in the platelets of the placental blood. Structural analysis of PD-ECGF purified to homogeneity from term placenta showed that the placental factor was differently processed in the N-terminus compared with the platelet protein and contained five extra amino acids (Figure 3 ). This is consistent with the observation that the placental factor migrated in SDS-gel electrophoresis as a component of 47 kDa (Figure 1 ), whereas the platelet factor migrates slightly faster, corresponding to a size of 45-46 kDa (Miyazono et al., 1987; Miyazono and Heldin, 1989) . The placental and platelet forms were approximately equipotent in their mitogenic activities on PAE cells; whether their structural difference is associated with other functional differences is currently being investigated. The purification of PD-ECGF to homogeneity from human placenta involved a 23 000-fold purification at a yield of 3.6%. The corresponding figures for the purification of PD-ECGF from human platelets are a 1 250 000-fold purification at a 14% yield ). The differences most likely result partly from the fact that placenta also contains other endothelial cell mitogens, e.g., FGFs (Moscatelli et al., 1986) , whereas PD-ECGF seems to be the only major mitogen in platelets for PAE cells . The placenta also contains growth inhibitors for endothelial cells, such as transforming growth factor-: (Frolik et al., 1983) , which may explain the increase in growth-promoting activity noticed after the ammonium sulfate precipitation step in the preparation procedure (Table 1) . Immunohistochemical staining of sections from term placenta revealed that PD-ECGF was present in stromal cells, whereas trophoblasts and endothelial cells were negative ( Figure 6 ). This is consistent with our previous finding that human foreskin fibroblasts in culture produced PD-ECGF . A staining along the sinusoids was also seen. This most likely represents adsorbed PD-ECGF derived from platelets of the maternal blood, because partial coagulation and activation of platelets would occur at some sites in the placental tissue during labor, as well as after delivery before freezing of the tissue. In addition to endothelial cells, trophoblasts are also possible targets for PD-ECGF secreted from stromal cells in the placenta, because PD-ECGF stimulates the growth not only of endothelial cells, but also of choriocarcinoma cell lines, which are derived from trophoblasts ( Figure 5 ). It remains to be invesVol. 1, July 1990 tigated, however, whether PD-ECGF promotes the growth of nontransformed trophoblasts. It is thus possible that, at a later stage of placental development, stromal PD-ECGF of the placenta may play a key role in angiogenesis through the promotion of growth of trophoblasts and endothelial cells, which build up the vascular network in direct contact with blood in sinuses and in vessels, respectively.
Apart from mitogenicity, PD-ECGF stimulates chemotaxis of endothelial cells . Furthermore, with the use of immunoblot analysis with anti-PD-ECGF specific serum, the factor has been found in porcine uterus and in cultured human vascular smooth muscle cells (Usuki et al., unpublished data) . It is thus possible that PD-ECGF also has a role at the early stages of placental development; PD-ECGF from uterus smooth muscle cells and stromal fibroblasts might promote the implantation of the blastocyste into the uterine wall by stimulating chemotaxis of trophoblasts.
Materials and methods Assay of growth promoting activity
Porcine aortic endothelial cells were cultured in Ham's F-10 medium (GIBCO, Grand Island, NY) supplemented with 100/% fetal calf serum (FCS) and antibiotics (Miyazono et al., 1987 
Purification of PD-ECGF from human placenta
A term human placenta was obtained from Department of Obstetrics, University Hospital, Uppsala, within 2 h after delivery and stored at -200C until use. All procedures were performed at 40C, unless otherwise described. The placenta was thawed at 40C overnight, dissected free from amnion membrane and the umbilical cord, and then ground in a meat grinder. The minced placenta (-450 g) was homogenized (Food Processor, Electrolux, Alingsas, Sweden, maximal speed for 5 min in N2 atmosphere) in four times its weight of 0.15 M NaCI, 10 mM imidazol buffer, pH 7.4, 5 mM dithiothreitol. The homogenate was cleared from debris by centrifugation for 10 min at 1300 x g and then filtered through two layers of cheesecloth. The filtrate was clarified by recentrifugation at 13 700 x g for 1 h and then diluted to 75 mM NaCI with distilled water; 30 g of dry QAE-Sephadex A-50 gel (Pharmacia-LKB, Uppsala, Sweden) was then added, and the slurry was mixed by shaking overnight. The gel was poured into a column (60 x 5 cm; Pharmacia-LKB) and washed with 75 mM NaCI, 10 mM imidazol buffer, pH 7.4; the sample was then eluted with 250 mM NaCI, 10 mM imidazol buffer, pH 7.4. Ammonium sulfate (247 g/l) in 50 mM sodium phosphate buffer, pH 7.4, was added to the eluate of the QAE-Sephadex column. After equilibration for 2 h, the precipitate was pelleted by centrifugation at 3000 x g for 30 min, then resuspended in phosphate-buffered saline (PBS); treated with 5 mM dithiothreitol at room temperature for 2 h; and dialyzed extensively against 50 mM NaCI, 10 mM Bis-tris(hydroxymethyl)aminomethane/HCI (Bis-Tris/HCI), pH 6.8. After filtration through a 0.22-,um filter (Millipore, Bedford, MA), the sample was applied to a 30-ml column (1.5 x 15 cm) of Q-Sepharose (Pharmacia-LKB) and eluted with a 400-mi linear gradient of NaCI from 100 mM to 200 mM in Bis-Tris, pH 6.8; the column was operated at a flow rate of 5 ml/min; and 1 0-mi fractions were collected. The fractions containing endothelial cell growth-promoting activity were pooled and subjected to a high-performance hydroxylapatite column (7.8 x 100 mm; Bio-Rad, South Richmond, CA) equipped with a guard column (4.0 x 50 mm; Bio-Rad). Immunoblotting SDS-gel electrophoresis was performed in 10%-1 8% gradient polyacrylamide gels under reducing conditions (Blobel and Dobberstein, 1975) . Samples on the gel were transferred to nitrocellulose membranes in a buffer containing 100% ethanol, 150 mM glycine, and 20 mM Tris-base, pH 8.4. The nitrocellulose membranes were incubated in 150 mM NaCI, 10 mM Tris-HCI, pH 7.4, 100/o bovine serum albumin (BSA; Fraction V, Boehringer Mannheim, Mannheim, FRG) to block non-specific binding, then incubated in a 1:50 dilution of a specific rabbit PD-ECGF antiserum , and washed twice with 150 mM NaCI, 10 mM Tris-HCI, pH 7.4 and twice with 150 mM NaCI, 10 mM Tris-HCI, pH 7.4, 0.050/% Triton X-1 00. The nitrocellulose membranes were then incubated with '251-labeled staphylococcal protein A (5 x 1 05 cpm/ml) and washed as described above. Blots were subjected to autoradiography.
Immunohistochemistry
Biopsies from term placentas-obtained from Department of Obstetrics, University Hospital, Uppsala-were frozen , preimmune serum (diluted 1:400), or rabbit anti-Factor Vil antiserum (diluted 1:400) and washed with PBS. In the second step, sections were incubated for 30-60 min with swine anti-rabbit IgG (Dakopatts) diluted 1:500 in PBS containing 4% BSA and then washed with PBS. In the third step, sections were incubated for 30-60 min with rabbit peroxidase/anti-peroxidase (rabbit-PAP; Dakopatts) diluted 1 :1000 in PBS containing 4% BSA. The peroxidase reaction was carried out by the use of a diethyl carbazole-containing buffer (Kaplow, 1975) , and the sections were counterstained with hematoxylin and mounted in glycerin-gelatin. Both the swine anti-rabbit IgG and the Fabbit-PAP reagent had been preabsorbed with normal human serum immobilized on CNBr-activated Sepharose-4B (Pharmacia-LKB) to suppress unspecific binding to the placental tissue. Control stainings included 1) exchange of the primary antiserum with preimmune serum from the same rabbit and 2) stainings with anti-PD-ECGF antiserum that had been preincubated with a threefold molar excess of purified PD-ECGF for 24 h at 4°C. Human chorionic gonadotropin-producing cells and macrophages were also visualized by immunohistochemistry. An anti-HCG rabbit antiserum was obtained commercially (Dakopatts) and used as recommended by the manufacturer. The tissue macrophage-specific monoclonal antibody RFD7 was kindly provided by Dr. Leonard Poulter (Department of Immunology, Royal Free Hospital, London, UK) (Poulter et al., 1986 ) and used at a concentration of 1 ,sg/ml. Sections were pretreated as described above and stained immunohistochemically with each of the antibodies, employing a biotin-avidin-peroxidase complex (ABC)-based system (Vectastain, Vector Laboratories, Burlingame, CA).
